Coronavirus

I am on the record as being, if not a convicted seasonal denier, at least insufficiently Christmassy. Last year I interviewed Noel Gallagher for the Christmas cover of a magazine and we bonded over our mutual dread of what our American friends call, dispiritingly, holidays. ‘Christmas Day’s the longest day, longer than D-Day — and more stressful,’ he moaned. ‘You’re sitting there exhausted, thinking, “And it’s only 11 o’clock”.’ For the avoidance of doubt, I love Christmas trees, holly, mistletoe, church services, chestnut stuffing and mince pies. I do not love schlepping round the shops, all playing Slade on a loop, in the sleet buying things people don’t want, and

Across Europe, hospitals have been filling up again with the second wave of coronavirus. France, Belgium, Germany, Switzerland and the Netherlands have all been hit, as has the Midwest of the United States. In England we’ve gone from fewer than 500 Covid-positive patients in hospital at the start of September to nearly 15,000 now. Each morning, we anxiously scrutinise the overnight figures. Thankfully, in the past week Covid inpatient numbers have begun to plateau — although they’ve still been rising in parts of the Midlands, London and Kent. So it’s an uneven picture. But unlike in March, community testing gives hospitals advance warning, so we’re able to adjust the provision

We have become used to Mondays bringing good news on the vaccine front. But the publication of interim results from the Astra Zeneca/Oxford University vaccine – AZD1222 – will certainly please the UK government. Not merely because this is the home-grown option and we have already ordered 100m shots, but because, shot for shot, it is considerably cheaper to buy and administer than the other vaccine candidates. The vaccine itself is less than a fifth of the price of the Pfizer vaccine. Moreover, it does not need storing and transporting at minus 70 Celsius – it can be kept at ordinary fridge temperatures (2 to 8 Celsius), greatly facilitating any

The ‘Danmask-19 trial‘ sought to test whether face masks are effective in preventing infection with SARS-CoV-2 (the virus that causes Covid-19) for the wearer. It found that the recommendation to wear surgical masks to supplement other public health measures ‘did not reduce the SARS-CoV-2 infection rate among wearers by more than half in a community’. So does this mean wearing masks is a waste of time? There are several reasons that drawing such a conclusion from this study might be unwise. A randomised controlled trial (RCT) is often – though not always – the best way of testing whether a treatment works, because RCTs guard against the biases inherent in many other